Novel Treatment Approaches in the Management of Hepatocellular
Carcinoma(HCC): What Managed Care Needs to Know
About Emerging Combination Regimens

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of HCC, including
how to translate the most recent data into clinical and administrative practice.

These are archives of live webinars held between March 18 to April 8, 2020.

If you participated in any of the live webinars, you are not eligible to
claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

Each session has its own specific valid dates

This series is supported by educational grants from
Eisai and Merck & Co.

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.


Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the US. In 2019, it was expected that liver cancer accounted for approximately 788,000 deaths globally, making it the second leading cause of cancer-related deaths worldwide. Prognosis is especially poor for those with unresectable HCC. Fortunately, new agents have recently been approved that provide new options for clinicians in the first-line setting. Additionally, targeted therapy and immunotherapy combinations have shown improved efficacy and safety in recent clinical trials. In this webinar series, attendees will learn about the latest data necessary to make appropriate formulary decisions and care for patients with HCC around these targeted and immunotherapy combination options, especially as more are approved and become available.

A Deeper Look into Targeted and Immunotherapeutic Combination Therapies in Hepatocellular Carcinoma (HCC): Improving Clinical and Economic Outcomes

  1. Identify current unmet clinical needs in the management of hepatocellular carcinoma (HCC) and evidence-based recommendations for the care of patients with these tumors
  2. Analyze the mechanistic rationales underlying recent targeted drug development, including combination regimens, in HCC
    and how they relate to HCC biology
  3. Asses the role of targeted and immunotherapeutic treatments, including combination regimens, in the management of HCC
    based on recent clinical trial data
  4. Compare and contrast the mechanisms of action, safety and efficacy of current and emerging targeted agents and immunotherapies, including combination regimens, in the treatment of HCC
          Physician, Nursing and CMCN credits valid to April 1, 2022

Improving Patient Adherence and Quality of Life in Hepatocellular Carcinoma (HCC): Anticipating and Managing Treatment Related Adverse Events Associated with Emerging Combination Regimens

  1. Identify challenges to patient adherence and quality of life in the use of targeted and immunotherapeutic agents, and their
    combinations, in HCC
  2. Examine adverse events commonly associated with targeted therapies and immunotherapies, both alone or in combination, used in HCC treatment
  3. Explore strategies to monitor and manage adverse events associated of emerging combination regimens in HCC in order to improve patient adherence and quality of life
  4. Review recent clinical data around the safety of targeted agents and immunotherapies and their effect on patient quality of life
  5. Assess how treatment strategies can be affected by adverse events based on patientís individualized needs
          Physician, Nursing and CMCN credits valid to April 1, 2022

Comparative Effectiveness and Coordinated Care in Hepatocellular Carcinoma (HCC): What Does Managed Care Need to Know about Targeted and Immunotherapy Combinations?

  1. Discuss key economic challenges surrounding management of patients with HCC and the need for more optimal medical
    intervention to reduce healthcare costs and improve patient quality of life
  2. Assess recent clinical data and managed care considerations of current and emerging targeted therapies and their emerging combinations and where these agents fit into the current HCC management paradigm
  3. Analyze methods to enable optimal cost management of targeted and immunotherapeutic agents, including combination regimens, to be realized by multiple HCC stakeholders including managed care organizations
  4. Examine strategies used by managed care organizations to facilitate high quality care for members with HCC and how emerging combination regimens will affect those strategies
          Physician, Nursing and CMCN credits valid to April 1, 2022